Teacher Retirement System of Texas Purchases New Shares in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Teacher Retirement System of Texas purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,120 shares of the life sciences company’s stock, valued at approximately $223,000.

Other hedge funds also recently made changes to their positions in the company. Assenagon Asset Management S.A. lifted its holdings in shares of Integra LifeSciences by 2,418.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company’s stock valued at $39,581,000 after purchasing an additional 1,728,480 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in Integra LifeSciences during the fourth quarter valued at $28,940,000. Paradigm Capital Management Inc. NY increased its position in Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock valued at $32,457,000 after acquiring an additional 901,600 shares during the last quarter. Lord Abbett & CO. LLC increased its position in Integra LifeSciences by 86.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock valued at $30,210,000 after acquiring an additional 618,773 shares during the last quarter. Finally, Norges Bank purchased a new stake in Integra LifeSciences during the fourth quarter valued at $8,967,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Price Performance

Shares of IART stock opened at $11.13 on Friday. Integra LifeSciences Holdings Corporation has a 52-week low of $11.06 and a 52-week high of $32.49. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.72 and a current ratio of 1.21. The firm has a market capitalization of $864.91 million, a P/E ratio of -29.29, a P/E/G ratio of 0.62 and a beta of 1.15. The stock has a 50 day moving average price of $12.70 and a 200 day moving average price of $18.31.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). The firm had revenue of $382.65 million for the quarter, compared to analysts’ expectations of $381.17 million. Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.55 earnings per share. As a group, sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on IART shares. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, April 11th. JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a research note on Friday, May 9th. JPMorgan Chase & Co. dropped their price objective on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company dropped their price objective on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and an average price target of $18.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.